BackNovo Nordisk Overview

Novo Nordisk Receivables

Track Novo Nordisk's receivables ($110B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$108.51B
26.41% YoYΔ $22.67B vs prior year quarter

Peer trimmed avg / median

Loading

Novo Nordisk Receivables History

Loading

Novo Nordisk vs. peers: Receivables Comparison

Loading

Novo Nordisk Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Novo Nordisk (NVO) FAQ

As of the most recent data (June 2026), NVO shows a receivables of $110B. That compares with $86B in the prior-year period — up 26.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVO's receivables is now $110B (was $86B) — a 26.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk is outperforming or lagging.

Tracking NVO's receivables over time shows whether Novo Nordisk is scaling, shrinking, or reshaping that part of the business. The current reading is $110B That compares with $86B in the prior-year period — up 26.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Novo Nordisk's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $110B) with ownership activity and broader fundamentals.

Novo Nordisk's receivables is $110B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.